Ipatasertib + Chemotherapy for Cancer

Not currently recruiting at 237 trial locations

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: National Cancer Institute (NCI)

Must not be taking: CYP3A inhibitors, CYP3A inducers

Disqualifiers: KRAS mutation, Brain metastases, Diabetes, Lung disease, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 3 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 1

Duration: up to 35 months

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a combination of chemotherapy (paclitaxel) and a drug called ipatasertib to determine if they can work together to shrink or halt the growth of certain solid tumors. These tumors typically cannot be removed with surgery, have spread locally, or have metastasized, and they possess specific genetic changes known as PTEN and AKT mutations. The trial aims to determine if adding ipatasertib can improve outcomes compared to chemotherapy alone. Suitable participants have solid tumors that are not breast-related, possess specific genetic mutations, and have experienced cancer progression despite previous treatments. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Will I have to stop taking my current medications?

The trial does not specify if you must stop taking your current medications, but you cannot take medications that are strong inhibitors or inducers of CYP3A enzymes. It's important to discuss your current medications with the trial team to ensure there are no interactions.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research shows that ipatasertib, when combined with paclitaxel, is generally safe and tolerable. In earlier studies, patients who took ipatasertib with chemotherapy experienced manageable side effects, such as fatigue and changes in blood counts, which are common in many cancer treatments.

One study found that ipatasertib with paclitaxel was well-tolerated by patients with various types of cancer. Another study found that while the combination caused some manageable side effects, it was overall safe for participants. Although some adverse effects were reported, they were not severe for most patients.

Other trials have studied this combination treatment for different cancers. The findings suggest that, although side effects can occur, they are often mild or moderate. Discuss any concerns with the trial team to understand what to expect during the trial. ^{1 2 3 4 5}

Why are researchers excited about this study treatment for cancer?

Researchers are excited about the combination of ipatasertib and paclitaxel for cancer treatment because it introduces a novel approach by targeting the AKT pathway, a key player in cancer cell growth and survival. Unlike standard chemotherapy, which broadly attacks rapidly dividing cells, ipatasertib specifically inhibits AKT, potentially leading to more effective cancer cell death with fewer side effects. This targeted action, combined with the well-known efficacy of paclitaxel, could enhance treatment outcomes and offer new hope for patients with advanced cancers.

What evidence suggests that this treatment might be an effective treatment for solid tumor cancers?

Research has shown that using ipatasertib with paclitaxel, the combination tested in this trial, may help treat certain cancers. In people with triple-negative breast cancer, this combination extended the time they lived without their cancer worsening. One study found that 73% of patients experienced tumor shrinkage, a positive result. These findings are especially promising for tumors with specific genetic changes like PTEN and AKT. Overall, the evidence suggests that adding ipatasertib to paclitaxel could help shrink tumors or keep them stable longer in these cases. ^{6 7 8 9 10}

Who Is on the Research Team?

Reva K Basho

Principal Investigator

SWOG Cancer Research Network

Are You a Good Fit for This Trial?

Adults with solid tumors that can't be surgically removed, have spread, and show an AKT genetic mutation. They must have progressed after taxane-based therapy within 6 months and meet specific health criteria including organ function tests. Excluded are those who've had prior AKT inhibitors, certain mutations, uncontrolled illnesses or bowel inflammation, or are pregnant.

Inclusion Criteria

Participants must be enrolled on the ComboMATCH Master Registration Trial EAY191

My cancer has an AKT mutation according to the ComboMATCH test.

I am enrolled in EAY191 and assigned to ComboMATCH for EAY191-S3 due to a specific mutation.

Exclusion Criteria

I can swallow pills without any issues.

Participants with known diabetes mellitus must meet specific criteria

My condition did not worsen within 6 months after receiving taxane-based therapy.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

1 visit (in-person)

Treatment

Participants receive paclitaxel intravenously on days 1, 8, and 15 and ipatasertib orally on days 1-21 of each 28-day cycle, for up to 35 cycles

up to 35 months

Monthly visits for each cycle

Follow-up

Participants are monitored for safety and effectiveness after treatment completion, with follow-up until death or 3 years after registration

up to 3 years

Regular follow-up visits

What Are the Treatments Tested in This Trial?

Interventions

• Ipatasertib
• Paclitaxel

Trial Overview

The trial is testing the combination of chemotherapy (paclitaxel) with a targeted drug called Ipatasertib in patients whose solid tumors carry an AKT mutation. The goal is to see if this combo can shrink these cancers or stop their growth more effectively than standard treatments.

How Is the Trial Designed?

Group I: Treatment (paclitaxel, ipatasertib) Experimental Treatment 6 Interventions

Patients receive paclitaxel IV on days 1, 8, and 15 and ipatasertib PO on days 1-21 of each cycle. Treatment repeats every 28 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI and blood collection throughout the trial. Patients also undergo a tumor biopsy during screening and optionally during follow-up.

Paclitaxel is already approved in United States, European Union, Canada for the following indications:

Approved in United States as Taxol for:

• Ovarian cancer
• Breast cancer
• Non-small cell lung cancer
• Kaposi's sarcoma

Approved in European Union as Taxol for:

• Ovarian cancer
• Breast cancer
• Non-small cell lung cancer
• Kaposi's sarcoma

Approved in Canada as Paclitaxel for:

• Ovarian cancer
• Breast cancer
• Non-small cell lung cancer
• Kaposi's sarcoma

Who Is Running the Clinical Trial?

National Cancer Institute (NCI)

Lead Sponsor

Trials

14,080

Recruited

41,180,000+

Published Research Related to This Trial

Combining paclitaxel with doxorubicin has shown impressive remission rates for metastatic breast cancer, with overall rates exceeding 90% and nearly 50% achieving complete remission, especially when administered in a specific sequence.

While other combinations of paclitaxel with drugs like cisplatin and vinorelbine have shown variable results, the doxorubicin/paclitaxel combination remains the most effective and tolerable treatment option currently available.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Paclitaxel-containing combination chemotherapy for metastatic breast cancer. Hortobagyi, GN., Ibrahim, N.[2018]

Taxol has been established as a standard treatment for non-small cell lung cancer and epithelial ovarian cancer, and is recommended for use after doxorubicin in advanced or metastatic breast cancer.

While Taxol is being investigated for use in other cancers like head and neck and prostate cancer, current trials have not shown it to be superior to existing treatments, indicating a need for further phase III studies and exploration of combinations with targeted therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Evidenced-based medicine and future direction of Taxol]. Hatae, M., Nakamura, T., Ohnishi, Y.[2015]

Paclitaxel is an effective treatment for treatment-refractory ovarian cancer, working by stabilizing microtubules to induce cytotoxicity, despite facing challenges like severe hypersensitivity reactions and formulation issues.

The drug is associated with significant side effects, including myelosuppression, mucositis, and neurotoxicity, which are dose-dependent, highlighting the need for careful management in clinical use.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Paclitaxel (taxol). Kohler, DR., Goldspiel, BR.[2019]

In the IPATential150 trial involving 1097 patients with metastatic castration-resistant prostate cancer, adding ipatasertib to abiraterone and prednisone significantly improved radiographic progression-free survival for patients with PTEN-loss tumors.

While ipatasertib was associated with a higher rate of serious adverse events and treatment discontinuation compared to placebo, its overall safety profile was considered tolerable, suggesting that with proper management, the side effects could be mitigated.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. Matsubara, N., de Bono, J., Sweeney, C., et al.[2023]

A woman with non-small cell lung cancer developed a photodistributed dermatitis as a side effect of nab-paclitaxel therapy, which worsened with each treatment cycle, highlighting the potential for skin reactions in patients receiving taxane chemotherapy.

The patient's condition improved with topical corticosteroids and strict sun avoidance, indicating that while photodermatoses can occur with taxane treatments, they can be managed effectively without necessarily stopping chemotherapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Nab-paclitaxel-associated photosensitivity: report in a woman with non-small cell lung cancer and review of taxane-related photodermatoses. Beutler, BD., Cohen, PR.[2020]

The combination of nab-paclitaxel, gemcitabine, and capecitabine was found to be well tolerated in a phase I study with 15 patients, establishing a maximum-tolerated dose (MTD) but showing only modest antitumor activity in metastatic pancreatic cancer.

Despite the regimen being generally safe, with a low incidence of severe hematologic toxicities, only 14.3% of patients had a partial response, indicating that optimizing dose intensity may be crucial for improving treatment outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Ko, AH., Truong, TG., Kantoff, E., et al.[2022]

Paclitaxel has demonstrated strong antitumor activity in various cancers, including ovarian, breast, and lung carcinoma, especially when combined with platinum compounds like cisplatin and carboplatin.

Recent large randomized trials in Europe have explored the effectiveness of paclitaxel in combination with platinum for treating non-small cell lung cancer, showing promising results and leading to ongoing studies on its use in preoperative settings and with radiotherapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer. Novello, S., Le Chevalier, T.[2019]

Paclitaxel and docetaxel are effective treatments for various solid tumors, with paclitaxel now considered first-line therapy for advanced ovarian cancer and both drugs showing significant activity in recurrent ovarian cancer.

Both taxanes are also effective in treating breast cancer and advanced non-small cell lung cancer (NSCLC), with ongoing research exploring their use in combination therapies and as adjuvant treatments to improve patient outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical overview of the taxanes. Goldspiel, BR.[2022]

In a study of 33 patients with progressive or recurrent non-small cell lung cancer (NSCLC) who had previously undergone platinum-based chemotherapy, Abraxane showed a partial response rate of 33.3%, with better outcomes in patients with squamous cell carcinoma (41.7% response) compared to those with adenocarcinoma (21.1%).

The treatment demonstrated a disease control rate of 75.8% and a median progression-free survival of five months, with manageable side effects, indicating that Abraxane is a potentially effective option for this patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy and safety of Abraxane in treatment of progressive and recurrent non-small cell lung cancer patients: A retrospective clinical study. Yuan, DM., Lv, YL., Yao, YW., et al.[2019]

In a study of 80 Italian patients with metastatic pancreatic cancer, treatment with nab-paclitaxel in combination with gemcitabine resulted in a median overall survival of 8 months and a median progression-free survival of 5 months, indicating its efficacy.

Nab-paclitaxel was well-tolerated and led to significant pain relief, with reductions in the tumor marker CA 19-9 correlating positively with overall survival, suggesting it may be a useful predictor of treatment outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer. De Luca, R., Blasi, L., Alù, M., et al.[2022]

Combination therapies using paclitaxel with non-anthracycline agents have shown promising response rates between 40% to 80% and median time to progression exceeding 6 months in phase II and III studies.

Further research through prospective, randomized phase III trials is needed to confirm the benefits of these combinations over older treatments, particularly regarding quality of life, response rates, and survival in metastatic breast cancer patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Paclitaxel plus nonanthracycline combinations in metastatic breast cancer. Perez, EA.[2015]

Taxol, when administered intravenously, has a well-established safety profile based on data from 655 patients, with myelosuppression, particularly neutropenia, identified as the main dose-limiting toxicity, which was less severe with a 3-hour infusion schedule.

Severe hypersensitivity reactions were effectively managed with a premedication regimen, and while mild to moderate peripheral neuropathy was observed, it rarely led to treatment discontinuation, indicating a generally manageable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Overview of Taxol safety. Onetto, N., Canetta, R., Winograd, B., et al.[2015]

In a phase II trial involving 50 patients with previously untreated metastatic breast cancer, the combination of capecitabine and albumin-bound paclitaxel demonstrated a significant overall response rate of 61%, with a clinical benefit rate of 76.1%.

The treatment was well tolerated, with a median progression-free survival of 10.6 months and median overall survival of 19.9 months, although some patients experienced grade 3 adverse events like pain and neutropenia.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer. Schwartzberg, LS., Arena, FP., Mintzer, DM., et al.[2015]

In a phase II trial involving 30 patients with untreated metastatic pancreatic adenocarcinoma, the combination of capecitabine and nab-paclitaxel demonstrated a promising objective response rate of 41.4% and a disease control rate of 76%.

The treatment was well tolerated, with most patients able to escalate the nab-paclitaxel dose after the first course, and the most common adverse events were manageable, including sensory neuropathy and neutropenia.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. Scheithauer, W., Kornek, G., Prager, G., et al.[2022]

Nab-paclitaxel (Abraxane(®)) has been approved by the FDA for treating breast cancer after chemotherapy failure, showing superior efficacy compared to traditional paclitaxel (Taxol(®)).

This new formulation not only demonstrates better effectiveness but also has less toxicity, which enhances its safety profile and therapeutic index, making it a promising option for combination therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Montero, AJ., Adams, B., Diaz-Montero, CM., et al.[2021]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC11443247/

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1 ...

Combining ipatasertib with first-line paclitaxel for triple-negative breast cancer (TNBC) improved progression-free survival (PFS), particularly in patients ...

2.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/39058425/

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1 ...

Combining ipatasertib with first-line paclitaxel for triple-negative breast cancer (TNBC) improved progression-free survival (PFS), particularly in patients ...

3.

roche.com

roche.com/media/releases/med-cor-2019-04-01

Roche's ipatasertib in combination with Tecentriq and ...

Combination treatment demonstrated a confirmed objective response rate (ORR) of 73% (95% CI 53-88%), irrespective of tumour biomarker status.

4.

clinicaltrials.gov

clinicaltrials.gov/study/NCT03337724?cond=(OVARIAN%20CANCER)%20OR%20(PIK3CA%20OR%20OPCML%20OR%20ERBB2%20OR%20AKT1%20OR%20CDH1%20OR%20CTNNB1%20OR%20PRKN)&rank=4&tab=results

A Study of Ipatasertib in Combination With Paclitaxel as ...

An unfavorable change in the health of a participant, including abnormal laboratory findings, that happens during a clinical study or within a certain amount of ...

5.

breast-cancer-research.biomedcentral.com

breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-025-02089-4

Ipatasertib combined with non-taxane chemotherapy for ...

Median PFS was 2.7 (95%CI, 1.5–4.1) and 3.8 (95%CI, 1.5–9.6) months; median OS was 15.5 (95%CI, 11.8–19.3) and 11.5 (95%CI, 8.8–25.1) months; ...

6.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC10322142/

Phase I Trial of Ipatasertib Plus Carboplatin ...

This trial evaluated the safety and efficacy of ipatasertib in combination with carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in patients ...

7.

sciencedirect.com

sciencedirect.com/science/article/pii/S0923753420360543

Antitumor activity of ipatasertib combined with chemotherapy

Ipatasertib and various therapeutic agents is safe and tolerable and has antitumor activity in multiple cancers. •. Further study of ipatasertib in cancers ...

8.

clinicaltrials.gov

clinicaltrials.gov/study/NCT03853707

Study Details | NCT03853707 | Ipatasertib in Combination ...

This phase I trial studies best dose of ipatasertib and how well it works with carboplatin with or without paclitaxel in treating patients with triple ...

9.

ascopubs.org

ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.1078

A phase I/IB study of ipatasertib in combination with ...

Ipatasertib (ipat) is an AKT inhibitor which has shown efficacy in combination with paclitaxel and atezolizumab in patients with triple negative breast cancer ...

10.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC5626630/

Ipatasertib plus paclitaxel versus placebo ...

Overall survival results are immature, with deaths in nine (15%) of 62 patients in the ipatasertib group and 17 (27%) of 62 patients in the ...